Proprotein Convertase Subtilisin/Kexin Type 9: From the Discovery to the Development of New Therapies for Cardiovascular Diseases

Table 2

Pharmacological approaches currently under development against PCSK9.

Approach	Name	Company	Ref.
mAb to LDLR binding domain of PCSK9	REGN727	Regeneron Pharmaceuticals Inc.	[131–134]
mAb to LDLR binding domain of PCSK9	mAb1	Amgen Inc.	[131]
mAb to LDLR binding domain of PCSK9	AMG 145	Amgen Inc.	[135]
mAb to LDLR binding domain of PCSK9	J16	Pfizer Inc.	[136]
Fab and IgG2 to catalytic domain	1D05	Merck Research Laboratories	[137]
Fab to C terminal domain	1G08	Merck Research Laboratories	[138]
mAb to LDLR binding domain of PCSK9	IB20	Merck Research Laboratories	[139]
Antisense oligonucleotide	ISIS 394814	Isis Pharmaceuticals, Inc.	[140]
Antisense oligonucleotide	SPC5001 SPC4061	Santaris Pharma A/S	[141, 142]
siRNA	PCS-A2/B2/C2	Alnylam Pharmaceuticals	[143]
Vaccine		Merck Research Laboratories	[144]